{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:47:29Z","timestamp":1787510849588,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Gout is a systemic disease from which some patients develop numerous painful tophi that adversely affect quality of life and functionality. Some patients treated with oral urate-lowering therapy are unable to maintain serum urate levels below 6\u00a0mg\/dL, and these patients, thus classified as having refractory or uncontrolled gout, often require therapy with pegloticase to reduce symptoms and tophaceous burden. The objective of this expert opinion review is to summarize the available evidence supporting the use of concomitant immunomodulators with pegloticase to prevent development of anti-drug antibodies (ADAs) when treating patients with uncontrolled gout.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Emerging evidence suggests that adding an immunomodulator to pegloticase therapy can substantially increase response rates to double those observed in phase 3 randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The combination of immunomodulation with pegloticase should be considered in routine clinical practice to improve durability of response, efficacy, and safety among patients with uncontrolled gout who otherwise have limited therapeutic options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11926-022-01055-9","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T04:03:00Z","timestamp":1644897780000},"page":"12-19","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9552-3351","authenticated-orcid":false,"given":"John K.","family":"Botson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert S. B.","family":"Baraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim R.","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christianne","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigid","family":"Freyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Abdellatif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehad","family":"Soloman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Lawrence","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"1055_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31:299\u2013316. https:\/\/doi.org\/10.1007\/s40259-017-0231-8.","journal-title":"BioDrugs"},{"key":"1055_CR2","doi-asserted-by":"publisher","unstructured":"\u2022 Strand, V. et al. Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents. BioDrugs. 2020;34:27-37. https:\/\/doi.org\/10.1007\/s40259-019-00394-x. High-quality review and discussion on the immunogenicity of biosimilars.","DOI":"10.1007\/s40259-019-00394-x"},{"key":"1055_CR3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","volume":"11","author":"S Ben-Horin","year":"2013","unstructured":"Ben-Horin S, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:444\u20137. https:\/\/doi.org\/10.1016\/j.cgh.2012.10.020.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1055_CR4","doi-asserted-by":"publisher","unstructured":"Ducourau, E. et al. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD Open. 2020;6:doi:https:\/\/doi.org\/10.1136\/rmdopen-2019-001047.","DOI":"10.1136\/rmdopen-2019-001047"},{"key":"1055_CR5","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","volume":"71","author":"CL Krieckaert","year":"2012","unstructured":"Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71:1914\u20135. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201544.","journal-title":"Ann Rheum Dis"},{"key":"1055_CR6","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1111\/jgh.12263","volume":"28","author":"DE Ong","year":"2013","unstructured":"Ong DE, Kamm MA, Hartono JL, Lust M. Addition of thiopurines can recapture response in patients with crohn\u2019s disease who have lost response to anti-tumor necrosis factor monotherapy. J Gastroenterol Hepatol. 2013;28:1595\u20139. https:\/\/doi.org\/10.1111\/jgh.12263.","journal-title":"J Gastroenterol Hepatol"},{"key":"1055_CR7","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1001\/jamainternmed.2013.7430","volume":"173","author":"JR Maneiro","year":"2013","unstructured":"Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med. 2013;173:1416\u201328. https:\/\/doi.org\/10.1001\/jamainternmed.2013.7430.","journal-title":"JAMA Intern Med"},{"key":"1055_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40744-020-00222-7","volume":"7","author":"JA Albert","year":"2020","unstructured":"Albert JA, Hosey T, LaMoreaux B. Increased efficacy and tolerability of pegloticase in patients with uncontrolled gout co-treated with methotrexate: a retrospective study. Rheumatol Ther. 2020;7:639\u201348. https:\/\/doi.org\/10.1007\/s40744-020-00222-7.","journal-title":"Rheumatol Ther"},{"key":"1055_CR9","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.semarthrit.2016.09.007","volume":"46","author":"AA Berhanu","year":"2017","unstructured":"Berhanu AA, Krasnokutsky S, Keenan RT, Pillinger MH. Pegloticase failure and a possible solution: immunosuppression to prevent intolerance and inefficacy in patients with gout. Semin Arthritis Rheum. 2017;46:754\u20138. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.09.007.","journal-title":"Semin Arthritis Rheum"},{"key":"1055_CR10","unstructured":"Bessen M.Y., Bessen S. Y. & Yung, C. M. Concomitant immunosuppressant use with pegloticase in patients with tophaceous gout- a case series. Int J Clin Rheumatol. 2019;14(6)."},{"key":"1055_CR11","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1016\/j.transproceed.2018.03.010","volume":"50","author":"B Freyne","year":"2018","unstructured":"Freyne B. A case report of immunosuppressant medication-associated polyarticular tophaceous gout successfully treated using the polyethylene glycol-conjugated uricase enzyme pegloticase. Transplantation Proc. 2018;50:4099\u2013101. https:\/\/doi.org\/10.1016\/j.transproceed.2018.03.010.","journal-title":"Transplantation Proc"},{"key":"1055_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1136\/annrheumdis-2020-eular.3891","volume":"79","author":"K Masri","year":"2020","unstructured":"Masri K, Winterling K, Lamoreaux B. Leflunomide co-therapy with pegloticase in uncontrolled gout. Ann Rheum Dis. 2020;79:454\u2013454. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.3891.","journal-title":"Ann Rheum Dis"},{"key":"1055_CR13","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1136\/annrheumdis-2020-eular.4642","volume":"79","author":"H Rainey","year":"2020","unstructured":"Rainey H, Baraf HS, Yeo AE, Lipsky PE. Companion immunosuppression with azathioprine increases the frequency of persistent responsiveness to pegloticase in patients with chronic refractory gout. Ann Rheum Dis. 2020;79:438.","journal-title":"Ann Rheum Dis"},{"key":"1055_CR14","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Botson JK, Peterson J. Pretreatment and coadministration with methotrexate improved durability of pegloticase response: an observational, proof-of-concept case series. J ClinRheumatol. 2020. https:\/\/doi.org\/10.1097\/RHU.0000000000001639. First methodical proof-of-concept exploration of pegloticase with immunomodulation.","DOI":"10.1097\/RHU.0000000000001639"},{"key":"1055_CR15","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1136\/annrheumdis-2020-eular.3932","volume":"79","author":"J Botson","year":"2020","unstructured":"Botson J, et al. Pegloticase response improvement by co-treatment with methotrexate: results from the MIRROR open-label clinical trial in patients with uncontrolled gout. Ann Rheum Dis. 2020;79:442.","journal-title":"Ann Rheum Dis"},{"key":"1055_CR16","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.40807","volume":"71","author":"M Chen-Xu","year":"2019","unstructured":"Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the united states and decadal trends: the national health and nutrition examination survey, 2007\u20132016. Arthritis Rheumatol. 2019;71:991\u20139. https:\/\/doi.org\/10.1002\/art.40807.","journal-title":"Arthritis Rheumatol"},{"key":"1055_CR17","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1002\/art.23803","volume":"58","author":"NL Edwards","year":"2008","unstructured":"Edwards NL. Treatment-failure gout: a moving target. Arthritis Rheumatol. 2008;58:2587\u201390. https:\/\/doi.org\/10.1002\/art.23803.","journal-title":"Arthritis Rheumatol"},{"key":"1055_CR18","unstructured":"Terkeltaub, R. Gout: diagnosis and management of gouty arthritis and hyperuricemia. 3rd edn. (Professional Communications, Inc, 2013)."},{"key":"1055_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/ceo.12749","volume":"45","author":"J Ao","year":"2017","unstructured":"Ao J, Goldblatt F, Casson RJ. Review of the ophthalmic manifestations of gout and uric acid crystal deposition. Clin Exp Ophthalmol. 2017;45:73\u201380. https:\/\/doi.org\/10.1111\/ceo.12749.","journal-title":"Clin Exp Ophthalmol"},{"key":"1055_CR20","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1001\/jamacardio.2019.3201","volume":"4","author":"AS Klauser","year":"2019","unstructured":"Klauser AS, et al. Dual-energy computed tomography detection of cardiovascular monosodium urate deposits in patients with gout. JAMA Cardiol. 2019;4:1019\u201328. https:\/\/doi.org\/10.1001\/jamacardio.2019.3201.","journal-title":"JAMA Cardiol"},{"key":"1055_CR21","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1093\/ndt\/12.9.1832","volume":"12","author":"V Nickeleit","year":"1997","unstructured":"Nickeleit V, Mihatsch MJ. Uric acid nephropathy and end-stage renal disease\u2013review of a non-disease. Nephrol Dial Transplant. 1997;12:1832\u20138. https:\/\/doi.org\/10.1093\/ndt\/12.9.1832.","journal-title":"Nephrol Dial Transplant"},{"key":"1055_CR22","doi-asserted-by":"publisher","unstructured":"Pascart, T. et al. Association of specific comorbidities with monosodium urate crystal deposition in urate-lowering therapy-naive gout patients: a cross-sectional dual-energy computed tomography study. J Clin Med. 2020;9:doi:https:\/\/doi.org\/10.3390\/jcm9051295.","DOI":"10.3390\/jcm9051295"},{"key":"1055_CR23","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/annrheumdis-2013-205095","volume":"74","author":"T Bongartz","year":"2015","unstructured":"Bongartz T, et al. Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis. 2015;74:1072\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205095.","journal-title":"Ann Rheum Dis"},{"key":"1055_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3810\/pgm.2012.11.2616","volume":"124","author":"PP Doghramji","year":"2012","unstructured":"Doghramji PP, Wortmann RL. Hyperuricemia and gout: new concepts in diagnosis and management. Postgrad Med. 2012;124:98\u2013109. https:\/\/doi.org\/10.3810\/pgm.2012.11.2616.","journal-title":"Postgrad Med"},{"key":"1055_CR25","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1093\/rheumatology\/kem058","volume":"46","author":"RG Thiele","year":"2007","unstructured":"Thiele RG, Schlesinger N. Diagnosis of gout by ultrasound. Rheumatology (Oxford). 2007;46:1116\u201321. https:\/\/doi.org\/10.1093\/rheumatology\/kem058.","journal-title":"Rheumatology (Oxford)"},{"key":"1055_CR26","doi-asserted-by":"publisher","unstructured":"FitzGerald, J. D. et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020. doi:https:\/\/doi.org\/10.1002\/acr.24180","DOI":"10.1002\/acr.24180"},{"key":"1055_CR27","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/annrheumdis-2017-212046","volume":"77","author":"N Dalbeth","year":"2018","unstructured":"Dalbeth N, et al. Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol. Ann Rheum Dis. 2018;77:364\u201370. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212046.","journal-title":"Ann Rheum Dis"},{"key":"1055_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13075-018-1782-x","volume":"20","author":"BF Mandell","year":"2018","unstructured":"Mandell BF, Yeo AE, Lipsky PE. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase. Arthritis Res Ther. 2018;20:286. https:\/\/doi.org\/10.1186\/s13075-018-1782-x.","journal-title":"Arthritis Res Ther"},{"key":"1055_CR29","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/art.10792","volume":"47","author":"F Perez-Ruiz","year":"2002","unstructured":"Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 2002;47:610\u20133. https:\/\/doi.org\/10.1002\/art.10792.","journal-title":"Arthritis Rheum"},{"key":"1055_CR30","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1186\/ar4318","volume":"15","author":"HS Baraf","year":"2013","unstructured":"Baraf HS, et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013;15:R137. https:\/\/doi.org\/10.1186\/ar4318.","journal-title":"Arthritis Res Ther"},{"key":"1055_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/RHU.0000000000000200","volume":"20","author":"HS Baraf","year":"2014","unstructured":"Baraf HS, Yood RA, Ottery FD, Sundy JS, Becker MA. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014;20:427\u201332. https:\/\/doi.org\/10.1097\/RHU.0000000000000200.","journal-title":"J Clin Rheumatol"},{"key":"1055_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/OARRR.S176951","volume":"10","author":"RN Cunha","year":"2018","unstructured":"Cunha RN, Aguiar R, Farinha F. Impact of pegloticase on patient outcomes in refractory gout: current perspectives. Open Access Rheumatol. 2018;10:141\u20139. https:\/\/doi.org\/10.2147\/OARRR.S176951.","journal-title":"Open Access Rheumatol"},{"key":"1055_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40744-019-0151-9","volume":"6","author":"RT Keenan","year":"2019","unstructured":"Keenan RT, Baraf HSB, LaMoreaux B. Use of pre-infusion serum uric acid levels as a biomarker for infusion reaction risk in patients on pegloticase. Rheumatol Ther. 2019;6:299\u2013304. https:\/\/doi.org\/10.1007\/s40744-019-0151-9.","journal-title":"Rheumatol Ther"},{"key":"1055_CR34","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3899\/jrheum.111375","volume":"39","author":"V Strand","year":"2012","unstructured":"Strand V, Khanna D, Singh JA, Forsythe A, Edwards NL. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase iii randomized controlled trials. J Rheumatol. 2012;39:1450\u20137. https:\/\/doi.org\/10.3899\/jrheum.111375.","journal-title":"J Rheumatol"},{"key":"1055_CR35","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/ar4497","volume":"16","author":"PE Lipsky","year":"2014","unstructured":"Lipsky PE, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16:R60. https:\/\/doi.org\/10.1186\/ar4497.","journal-title":"Arthritis Res Ther"},{"key":"1055_CR36","unstructured":"KRYSTEXXA (pegloticase injection) [prescribing information]. Horizon therapeutics."},{"key":"1055_CR37","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.2011.1169","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy JS, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306:711\u201320. https:\/\/doi.org\/10.1001\/jama.2011.1169.","journal-title":"JAMA"},{"key":"1055_CR38","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13075-020-02254-4","volume":"22","author":"N Schlesinger","year":"2020","unstructured":"Schlesinger N, Edwards NL, Yeo AE, Lipsky PE. Development of a multivariable improvement measure for gout. Arthritis Res Ther. 2020;22:164. https:\/\/doi.org\/10.1186\/s13075-020-02254-4.","journal-title":"Arthritis Res Ther"},{"key":"1055_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13075-017-1396-8","volume":"19","author":"LH Calabrese","year":"2017","unstructured":"Calabrese LH, Kavanaugh A, Yeo AE, Lipsky PE. Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. Arthritis Res Ther. 2017;19:191. https:\/\/doi.org\/10.1186\/s13075-017-1396-8.","journal-title":"Arthritis Res Ther"},{"key":"1055_CR40","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Khanna, D. & Khanna, P. P. Reducing immunogenicity of pegloticase (RECIPE) with concomitant use of mycophenolate mofetil in patients with refractory gout\u2014 results of a phase ii double blind randomized controlled trial. 2020. Early phase II randomized controlled trial demonstrating improved response rates in patients with uncontrolled gout treated with pegloticase and immunomodulation.","DOI":"10.1136\/annrheumdis-2021-eular.3111"},{"key":"1055_CR41","unstructured":"\u2022 Abdellatif, A. et al. A multicenter, open-label, efficacy and safety study of pegloticase in patients with uncontrolled gout who have undergone kidney transplantation: early data report. Arthritis Rheumatol. 2020;72. Early open-label study demonstrating efficacy and safety of pegloticase and immunomodulation in renal transplant patients with uncontrolled gout."},{"key":"1055_CR42","unstructured":"Results from PROTECT Trial Evaluating KRYSTEXXA\u00ae (pegloticase injection) in kidney transplant recipients with uncontrolled gout presented as Part of American Society of Nephrology (ASN) Kidney Week. Horizon Therapeutics, 4 Nov. 2021, https:\/\/ir.horizontherapeutics.com\/news-releases\/news-release-details\/results-protect-trial-evaluating-krystexxar-pegloticase. Press release."},{"key":"1055_CR43","unstructured":"Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA\u00ae\u00a0(pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout. Horizon Therapeutics, 10 Jan. 2022, https:\/\/ir.horizontherapeutics.com\/news-releases\/news-release-details\/horizon-therapeutics-plc-submits-supplemental-biologics-license."},{"key":"1055_CR44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.semarthrit.2021.01.005","volume":"51","author":"RT Keenan","year":"2021","unstructured":"Keenan RT, et al. The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review. Semin Arthritis Rheum. 2021;51:347\u201352. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.01.005.","journal-title":"Semin Arthritis Rheum"},{"key":"1055_CR45","doi-asserted-by":"crossref","unstructured":"\u2022 LaMoreaux, B., Francis-Sedlak, M., Svensson, K. & Holt, R. Immunomodulation co-therapy with pegloticase: database trends 2014-2019. Ann Rheum Dis. 2020;79:108. Retrospective database analysis showcasing the increasing trend in immunomodulation use with pegloticase over a 5-year period.","DOI":"10.1136\/annrheumdis-2020-eular.3893"},{"key":"1055_CR46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1756-0500-7-54","volume":"7","author":"RA Yood","year":"2014","unstructured":"Yood RA, Ottery FD, Irish W, Wolfson M. Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials. BMC Res Notes. 2014;7:54. https:\/\/doi.org\/10.1186\/1756-0500-7-54.","journal-title":"BMC Res Notes"},{"key":"1055_CR47","unstructured":"Imuran (azathioprine) [prescribing information]. Sebela."},{"key":"1055_CR48","unstructured":"Methotrexate [prescribing information]. Hospira."},{"key":"1055_CR49","unstructured":"Arava (leflunomide) [prescribing information]. Sanofi-Aventis."},{"key":"1055_CR50","unstructured":"Cellcept (mycophenolate mofetil) [prescribing information]. Genentech."},{"key":"1055_CR51","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Botson, J. K. et al. Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR). J Rheumatol. 2021;48:767-774. https:\/\/doi.org\/10.3899\/jrheum.200460. Open-label trial demonstrating 6-month sustained therapeutic response after combination therapy with pegloticase and methotrexate compared to pegloticase monotherapy.","DOI":"10.3899\/jrheum.200460"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-022-01055-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-022-01055-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-022-01055-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T04:25:35Z","timestamp":1645590335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-022-01055-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1007\/s11926-022-01055-9","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"6 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Standards"}},{"value":"Dr. Botson has received research support from Horizon Therapeutics and Allena Pharmaceuticals as a principal investigator. He has received consulting\/speaker fees from Horizon Therapeutics. He has participated on a Data Safety Monitoring Board\/Advisory Board for Horizon Therapeutics.Dr. Baraf has received consulting\/speaker fees from Horizon Therapeutics, and research grants or support from Horizon Therapeutics as an investigator.Dr. Keenan has been or is a consultant with Horizon Therapeutics, Arthrosi Therapeutics, Selecta Biosciences, Atom Biosciences, and Sobi Pharma. He has received honoraria\/speaker fees from Horizon Therapeutics.Dr. Albert serves on a speaker bureau for Horizon Therapeutics. He has received consulting\/speaker fees from Horizon Therapeutics. He has received travel support from Horizon Therapeutics. He has participated on an advisory board for Horizon Therapeutics.Dr. Masri has been or is a consultant with Guidepoint Global. He has received speaker fees\/honoraria from Horizon Therapeutics, Eli Lilly, and Pfizer. He has received payment for expert testimony from Cantor & Associates. He has participated on an advisory board for Horizon Therapeutics. He owns stock\/stock options in Horizon Therapeutics, Gilead, Corbus Pharmaceutical, and Aurinia Pharma.Dr. Peterson has received consulting\/speaker fees from Horizon Therapeutics. He has participated on an advisory board for Horizon Therapeutics. He reports other financial\/non-financial interests from Horizon Therapeutics.Dr. Yung has received consulting\/speaker fees from Horizon Therapeutics. She has participated on an advisory board for Horizon Therapeutics.Dr. Freyne declares no conflict of interest.Dr. Amin has received speaker fees\/honoraria from Horizon Therapeutics and Eli Lilly.Dr. Abdellatif has received consulting\/speaker fees from Horizon Therapeutics. He has received payment for expert testimony from Horizon Therapeutics. He has participated on an advisory board for Horizon Therapeutics. He has received travel support from Horizon Therapeutics.Dr. Nehad Soloman serves on a speaker bureau for Horizon Therapeutics.Dr. N. Lawrence Edwards has received consulting fees from Horizon Therapeutics, Shanton Pharma, and Atom Biosciences and Pharmaceuticals. He has received payment for expert testimony from Takeda Pharmaceuticals.Dr. Strand reports consulting fees from AbbVie, Amgen, Arena, Aria, AstraZeneca, BMS, Boehringer Ingelheim, Celltrion, CORRONA, Crescendo\/Myriad, EMD Serono, Equillium, Flexion, Galapagos, Genentech\/Roche, Gilead, GSK, Horizon, Ichnos, Inmedix, Janssen, Kiniksa, Eli Lilly, Merck, MiMedx, Novartis, Pfizer, Regeneron, Rheos, R-Pharma, Samsung, Sandoz, Sanofi, Scipher, Servier, Setpoint, Sun Pharma, and UCB, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}